Continuous Glucose Monitoring Use in Clinical Trials for On-Market Diabetes Drugs

Continuous Glucose Monitoring Use in Clinical Trials for On-Market Diabetes Drugs

To the best of our knowledge, there are no published data on the historical and recent use of CGM in clinical trials of pharmacological agents used in the treatment of diabetes. We analyzed 2,032 clinical trials of 40 antihyperglycemic therapies currently on the market with a study start date betwee...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical diabetes 2021-04, Vol.39 (2), p.160-166
Hauptverfasser: Fox, Bradley Q, Benjamin, Peninah F, Aqeel, Ammara, Fitts, Emily, Flynn, Spencer, Levine, Brian, Maslak, Elizaveta, Milner, Rebecca L, Ose, Benjamin, Poeschla, Michael, Ray, Meghna, Serino, Maeve, Shah, Sahaj S, Close, Kelly L
Format: Artikel
Sprache:eng
Schlagworte:
Clinical trials
Diabetes
Disease management
Glucose monitoring
Glycemic index
Prescription drugs
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To the best of our knowledge, there are no published data on the historical and recent use of CGM in clinical trials of pharmacological agents used in the treatment of diabetes. We analyzed 2,032 clinical trials of 40 antihyperglycemic therapies currently on the market with a study start date between 1 January 2000 and 31 December 2019. According to ClinicalTrials.gov, 119 (5.9%) of these trials used CGM. CGM usage in clinical trials has increased over time, rising from
ISSN:0891-8929
1945-4953
DOI:10.2337/cd20-0049